• 沒有找到結果。

Liv e r w e ight ( g )

N/A
N/A
Protected

Academic year: 2021

Share "Liv e r w e ight ( g )"

Copied!
18
0
0

加載中.... (立即查看全文)

全文

(1)

Table. 2-1. Effect of FMAC on 0, 4, 8 weeks body weight of CCl4 chronic treated rats.

Body weight (g) Group Doses

(g/kg/day)

0 week 4 weeks 8 weeks

Control 244.5 ± 5.1 341.0 ± 8.0 449.3 ± 7.1 CCl4 + VEH 245.3 ± 5.4 313.7 ± 6.7# 399.2 ± 16.3# CCl4 + SIL 0.2 244.3 ± 4.2 312.6 ± 7.2# 420.5 ± 21.9 CCl4 + FMAC 0.5 248.4 ± 4.7 301.2 ± 7.0## 401.8 ± 10.39 CCl4 + FMAC 1.0 247.8 ± 5.1 308.5 ± 9.2# 407.2 ± 10.94 CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. SIL 0.2g/kg/day or FMAC ( 0.5 or 1.0 g/kg/day) was administered orally from week 4 to the end of the experiment.Values are mean ± S.E. (n = 12) P#<0.05, P##<0.01 compared with the control group. VEH: vehicle; SIL:

Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(2)

Table. 2-2. Effect of FMAC on liver SOD, Catalase, GSH-Px activity. in CCl4 chronic treated rats.

Group Doses (g/kg/day)

SOD (U/mg protein)

Catalase (U/mg protein)

GSH-Px (U/mg protein) Control 30.28 ± 1.5 54.43 ± 1.8 1264.5 ± 45.9 CCl4 + VEH 14.46 ± 1.2### 38.71 ± 2.6### 984.6 ± 17.6##

CCl4 + SIL 0.2 15.70 ± 2.7 42.68 ± 1.6 1019.2 ± 25.6 CCl4 + FMAC 0.5 16.42 ± 1.2 47.37 ± 4.0 997.4 ± 33.7 CCl4 + FMAC 1.0 15.57 ± 1.0 47.83 ± 3.0 1072.0 ± 87.2

CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. SIL 0.2g/kg/day or FMAC ( 0.5 or 1.0 g/kg/day) was administered orally from week 4 to the end of the experiment.Values are mean ± S.E (n = 12).

P##<0.01, P###<0.001 compared with the control group. VEH: vehicle; SIL:

Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(3)

Table. 2-3. List of liver genes expression in CCl4 chronic treated rats.

Gene Name ID A B B / A

CCl4 /

control ratio

CCl4 / FMAC ratio

ratio Signal transducation

Ctsl--cathepsin L H3028F03 5.614 2.087 0.37

Gnb2l1--guanine nucleotide binding pro H3083H02 6.306 2.713 0.43 Gnb2l1--guanine nucleotide binding pro H3027D10 5.191 2.34 0.45 Abl1--v-abl Abelson murine leukemia on H3019F05 4.602 2.145 0.47 Ran--RAN, member RAS oncogene family H3154A03 4.471 2.281 0.51 Gnai2--guanine nucleotide binding prot H3106F07 4.273 2.173 0.51

Matrix

Col3a1--procollagen, type III, alpha 1 H3124H10 9.813 2.196 0.22 Col1a1--procollagen, type I, alpha 1 H3119H03 7.855 2.272 0.29 Acp5--acid phosphatase 5, tartrate res H3007G06 6.35 2.135 0.34

Calr--calreticulin H3021G11 6.051 2.039 0.34

Ero1l-pendin--ERO1-like H3125G05 6.432 2.222 0.35 Lbp--lipopolysaccharide binding protein H3086G08 6.031 2.088 0.35 Krt2-8--keratin complex 2, basic, gene H3014H12 5.035 1.75 0.35 Actx--melanoma X-actin H3018D09 6.137 2.299 0.37 Lypla1--lysophospholipase 1 J1043F12 4.329 1.733 0.40 Actg--actin, gamma, cytoplasmic H3114E08 6.326 2.541 0.40 Hbb-b1--hemoglobin, beta adult major c H3123E05 4.705 1.944 0.41

Syn1--synapsin I H3028D10 5.042 2.187 0.43

Got2--glutamate oxaloacetate transaminase H3157D01 4.424 1.955 0.44 Tuba2--tubulin alpha 2 H3024D08 4.334 1.982 0.46 Apoa1--apolipoprotein A-I H3043A10 5.179 2.383 0.46 P4hb--prolyl 4-hydroxylase, beta polyp H3125C05 5.161 2.353 0.46

(4)

Table. 2-3. (continued)

Protein

H19--H19 fetal liver mRNA H3133G06 11.203 2.004 0.18 Rps6--ribosomal protein S6 L0264E06 6.162 2.052 0.33 Rpl3--ribosomal protein L3 H3011F03 6.295 2.213 0.35 Rpl26--ribosomal protein L26 H3126H12 5.79 2.044 0.35 Rps24--ribosomal protein S24 H3145D11 5.793 2.046 0.35 Rpl5--ribosomal protein L5 H3028D03 5.123 1.869 0.36 Rps19--ribosomal protein S19 H3146B07 6.862 2.459 0.36 Rpl37a--ribosomal protein L37a H3134G11 5.925 2.307 0.39 Rpl41--ribosomal protein L41 H3157D06 5.906 2.302 0.39 Rpl7--ribosomal protein L7 H3147G04 5.403 2.084 0.39 Rplp1--ribosomal protein, large, P1 H3140H04 6.347 2.547 0.40 Rps7--ribosomal protein S7 H3122C10 6.042 2.503 0.41 Rpl13a--ribosomal protein L13a H3136G06 5.434 2.239 0.41

Plf--proliferin C0118D06 4.548 1.866 0.41

Arbp--acidic ribosomal phosphoprotein H3118D03 6.081 2.547 0.42 Rps4x--ribosomal protein S4, X-linked H3120D10 6.079 2.558 0.42 Rpl3--ribosomal protein L3 H3112F08 5.575 2.367 0.42 Rps12--ribosomal protein S12 H3112B02 6.61 2.751 0.42 Rps17--ribosomal protein S17 H3118G04 6.273 2.632 0.42 Rps5--ribosomal protein S5 H3112G01 6.223 2.656 0.43 Rps8--ribosomal protein S8 H3119A09 5.263 2.277 0.43 Rps16--ribosomal protein S16 H3115B08 5.712 2.532 0.44 Rps28--ribosomal protein S28 H3099D03 5.345 2.376 0.44 Rps15--ribosomal protein S15 H3150B01 6.028 2.75 0.46 Rps3--ribosomal protein S3 H3124H06 5.669 2.652 0.47 Rpl9--ribosomal protein L9 H3112A09 4.469 2.151 0.48 Trt--translationally regulated transcr H3113H02 4.443 2.12 0.48 Rps16--ribosomal protein S16 H3112H10 5.711 2.764 0.48 Rpl36--ribosomal protein L36 H3117D06 4.94 2.351 0.48 Pabpc1--poly A binding protein, cytopl H3107F01 3.418 1.639 0.48 Rpl29--ribosomal protein L29 H3004G11 3.839 1.898 0.49

(5)

Table. 2-3. (continued)

Rpl23--ribosomal protein L23 H3013F03 4.822 2.435 0.50

Ubc--ubiquitin C H3124H08 4.059 2.015 0.50

(6)

0 5 10 15 20

Liv e r w e ight ( g )

*

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-1.

Effect of the FMAC on CCl4 chronic treated rats liver weight. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Data are Values are mean ± S.E. (n = 12)

*P<0.05 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin;

FMAC: filtrate of fermented mycelia of Antrodia camphorata

(7)

0 1 2 3

Sple e n w e ight ( g )

###

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

*

Fig. 2-2.

Effect of the FMAC on spleen weight of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group. *P<0.05 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(8)

0 200 400 600

800 ControlCCl4 + VEH

CCl4+ SIL 0.2g/kg/day CCl4+ FMAC 0.5g/kg/day CCl4+ FMAC 1.0g/kg/day

GP T ( U /L )

4 6 8

weeks

###

###

* ###

*

Fig. 2-3.

Effect of the FMAC on GPT activities of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group. *P<0.05compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(9)

0 300 600 900 1200

Control CCl4 + VEH

CCl4 + SIL 0.2g/kg/day CCl4 + FMAC 0.5g/kg/day CCl4 + FMAC 1.0g/kg/day

4 6 8

weeks

GOT ( U /L )

###

###

###

**

* *

Fig. 2-4.

Effect of the FMAC on GOT activities of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group.*P<0.05, **P<0.01 compared with the CCl4+ VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(10)

0.0 0.5 1.0 1.5 2.0

A L B ( g /dl)

###

*

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-5.

Effect of the FMAC on serum albumin (ALB) concentration of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12). ###P<0.001 compared with the control group.*P<0.05 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(11)

0.0 0.2 0.4 0.6 0.8

A /G rat io

###

*

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-6.

Effect of the FMAC on serum A/G ratio of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group.*P<0.05 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(12)

0 10 20 30 40

P T (sec)

###

*

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-7.

Effect of the FMAC on prothrombin time of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group.*P<0.05 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(13)

0 50 100 150 200

Liv e r Prot e in ( m g/g t is s ue )

**

###

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

*

Fig. 2-8.

Effect of the FMAC on liver protein contents of CCl4 chronic treated rats. CCl4

was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks.

FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12). ###P<0.001 compared with the control group. *P<0.05,.**P<0.01 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(14)

0.0 0.5 1.0 1.5 2.0

L P O ( n mo le M D A /mg pr ot e in )

###

**

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-9.

Effect of the FMAC on liver lipid peroxidation (LPO) of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

###P<0.001 compared with the control group. **P< 0.01compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(15)

0 300 600 900 1200 1500 1800

H y drox y p roline ( µg/g t is s ue )

###

**

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-10.

Effect of the FMAC on liver hydroxyproline contents of CCl4 chronic treated rats. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n=12).

###P<0.001 compared with the control group. **P<0.01 compared with the CCl4 + VEH group. VEH: vehicle; SIL: Silymarin; FMAC: filtrate of fermented mycelia of Antrodia camphorata

(16)

0 1 2 3 4

GS H ( µm o le /g t is s ue )

*

Control

VEH SIL

0.5 1.0 FMAC(g/kg/day) CCl4

Fig. 2-11.

Effect of the FMAC on liver glutathione contents of CCl4 chronic treated rats.

CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC (0.5 or 1.0 g/kg/day) or Silymarin (0.2g/kg) was administered orally from week 4 to the end of the experiment. Values are mean ± S.E. (n = 12).

*P<0.05 compared with the CCl4 group. VEH: vehicle; SIL: Silymarin; FMAC:

filtrate of fermented mycelia of Antrodia camphorata

(17)

(A) (B)

(C) (D)

Fig. 2-12.

The photomicrographs of liver section taken from rats and stained with hematoxylin-eosin. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC or Silymarin was administered orally from week 4 to the end of the experiment. (A) Normal control (B) CCl4, Note that inflammatory cell infiltration, massive fatty changes and centribular necrosis was

(18)

(A) (B)

(C) (D)

Fig. 2-13.

The photomicrographs of liver section taken from rats and stained with Masson’s trichrome. CCl4 was administered by gavaging twice a week at a dose of 0.5 ml/rat for 8 weeks. FMAC or Silymarin was administered orally from week 4 to the end of the experiment. (A) Normal control (B) CCl4. Note that displaying bundles of collagen surrounding the lobules, with hemorrhage and necrosis was observed. (C) CCl4 + Silymarin (D) CCl4 + FMAC 1.0 g/kg/day

參考文獻

相關文件

好了既然 Z[x] 中的 ideal 不一定是 principle ideal 那麼我們就不能學 Proposition 7.2.11 的方法得到 Z[x] 中的 irreducible element 就是 prime element 了..

volume suppressed mass: (TeV) 2 /M P ∼ 10 −4 eV → mm range can be experimentally tested for any number of extra dimensions - Light U(1) gauge bosons: no derivative couplings. =&gt;

For pedagogical purposes, let us start consideration from a simple one-dimensional (1D) system, where electrons are confined to a chain parallel to the x axis. As it is well known

The observed small neutrino masses strongly suggest the presence of super heavy Majorana neutrinos N. Out-of-thermal equilibrium processes may be easily realized around the

incapable to extract any quantities from QCD, nor to tackle the most interesting physics, namely, the spontaneously chiral symmetry breaking and the color confinement.. 

(1) Determine a hypersurface on which matching condition is given.. (2) Determine a

• Formation of massive primordial stars as origin of objects in the early universe. • Supernova explosions might be visible to the most

• elearning pilot scheme (Four True Light Schools): WIFI construction, iPad procurement, elearning school visit and teacher training, English starts the elearning lesson.. 2012 •